Status:
COMPLETED
Mifepristone and Misoprostol for Midtrimester Termination of Pregnancy in Uzbekistan
Lead Sponsor:
Gynuity Health Projects
Conditions:
Abortion in Second Trimester
Eligibility:
FEMALE
Brief Summary
The primary goal is to examine the efficacy and feasibility of a mifepristone-misoprostol medical abortion regimen in terminating pregnancies 13-22 weeks in Uzbekistan.
Eligibility Criteria
Inclusion
- Meet legal criteria to obtain abortion
- Have an ongoing pregnancy of 13-22 weeks gestation
- Be willing to undergo a surgical completion if necessary
- Have no contraindications to study procedures, according to provider
- Be willing and able to consent to procedure, either by reading consent document or by having consent document read to her
- Be willing to follow study procedures
Exclusion
- Known previous transmural uterine incision
- Known allergy to mifepristone or misoprostol/prostaglandin or other contraindications to the use of mifepristone or misoprostol
- Any contraindications to vaginal delivery, including placenta previa
Key Trial Info
Start Date :
September 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2015
Estimated Enrollment :
135 Patients enrolled
Trial Details
Trial ID
NCT02235155
Start Date
September 1 2014
End Date
November 1 2015
Last Update
January 14 2016
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Bukhara Maternity House No. 1
Bukhara, Uzbekistan
2
Samarkand Perinatal Center
Samarkand, Uzbekistan
3
Clinic No. 2, Tashkent Medical Academy
Tashkent, Uzbekistan